পদ্ধতির তুলনা করুন
নির্বাচিত পদ্ধতিগুলো পাশাপাশি পর্যালোচনা করুন; যে সারিগুলোয় পার্থক্য আছে সেগুলো চিহ্নিত করা হয়।
| প্রাগম্যাটিক ফেজ II ক্লিনিক্যাল ট্রায়াল× | প্রথম-মানব-পরীক্ষা (First-in-Human) মাত্রা-বৃদ্ধি বিষয়ক গবেষণা× | |
|---|---|---|
| ক্ষেত্র | মহামারীবিদ্যা | মহামারীবিদ্যা |
| পরিবার | Process / pipeline | Process / pipeline |
| উদ্ভবের বছর≠ | Pragmatic framework: 1967; Phase II application: 1990s–2000s | 1960s (formal regulatory framework established ~1963–1970s) |
| প্রবর্তক≠ | Conceptual basis: Daniel Schwartz & Joseph Lellouch (pragmatic vs. explanatory distinction, 1967); applied to Phase II context by drug developers and trialists from the 1990s onward | Regulatory and clinical pharmacology community; formalized in U.S. FDA IND regulations (1963) and ICH guidelines |
| ধরন≠ | Interventional study design | Interventional clinical study design |
| মৌলিক উৎস≠ | Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648. DOI ↗ | Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI ↗ |
| অপর নাম | pragmatic Phase II trial, real-world Phase II trial, Phase II pragmatic RCT, Phase IIb pragmatic trial | Phase 1 trial, first-in-human study, FIH study, dose-escalation study |
| সম্পর্কিত | 6 | 6 |
| সারসংক্ষেপ≠ | A pragmatic Phase II clinical trial is an early-to-mid-stage interventional study that evaluates a new treatment's preliminary efficacy and safety under conditions that approximate real-world clinical practice rather than tightly controlled experimental settings. It sits between pure explanatory Phase II trials and large pragmatic Phase III confirmatory trials, prioritising practical feasibility and clinical relevance while still generating the signal needed to justify further development. | A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials. |
| ScholarGateডেটাসেট ↗ |
|
|